PROTOKOLwiki
COMPOUNDS / NOOTROPIC / NOOPEPT
NOOTROPIC

NOOPEPT

LOW RISK
BEST FOR:Cognition●●●●●●●○○○7/10
NOOPEPT · OMBERACETAM · GVS-111 · N-PHENYLACETYL-L-PROLYLGLYCINE ETHYL ESTER · N-PHENYLACETYL-L-PROLYL-GLYCINE ETHYL ESTER · NOPEPT
NootropicDipeptideSoviet/RussianCognitive EnhancerNeuroprotectiveAntioxidant

Synthetic dipeptide nootropic developed in Russia, enhancing memory and neuroprotection at very low doses.

ROUTE / DOSAGE
LOW5mg
STANDARD10-20mg
HIGH30mg+
Note: Take with food; oral bioavailability is low but clinically active
CYCLE
Daily use acceptable cycling recommended for tolerance management
BIOAVAILABILITY
low oral (~10%) higher sublingual (~20%)
ACTIVE DURATION
3-6h (subjective)
STORAGE
Room temperature dry away from light
HALF-LIFE
30-60 min (parent) metabolites active longer (plasma)
DURATION BREAKDOWN
Total3-6 hours
Onset30-60min oral, 15-30min sublingual, <5min intranasal
Come up30-60 min
Peak1-2 hours
Offset1-3 hours
After effects2-4 hours
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
7 documented
Enhanced memory consolidation and retrieval
Mild anxiolytic action
Neuroprotective and antioxidant effects
Improved cognitive function and focus
Anti-inflammatory activity
Potential antidiabetic and metabolic benefits
Low effective dose relative to other nootropics
§ 02 — RISKS
Insufficient long-term human safety data; most evidence is preclinical or from Russian clinical trials
Headache and irritability reported at higher doses
Sleep disturbances possible with evening dosing
One key study on BDNF and microglia mechanisms has been retracted (PMID 33644478)
Potential for unforeseen interactions with other cognitive enhancers or medications
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

Noopept was developed in Russia as a dipeptide analog of piracetam, with an effective dose approximately 1000 times lower than piracetam. Preclinical studies demonstrate neuroprotective effects in models of brain ischemia, cognitive deficiency, and diabetes, including protection of pancreatic beta cells via antigenotoxic mechanisms. The compound increases NGF and BDNF expression and activates HIF-1, but does not stimulate cell proliferation, suggesting a low mitogenic risk profile. Animal studies show antidiabetic properties including reduced blood glucose and protection against end-organ complications. However, robust large-scale human clinical trials remain limited; most evidence derives from Russian preclinical and early clinical research, and one key study on spinal microglia (PMID 33644478) has been retracted.

§ 06 — SOURCES
[1]
Cognitive Enhancer Noopept Activates Transcription Factor HIF-1 (PMID 33119829)
pubmed.ncbi.nlm.nih.gov ↗
[2]
Effects of noopept on ocular, pancreatic and renal histopathology in streptozotocin induced prepubertal diabetic rats (PMID 36946173)
pubmed.ncbi.nlm.nih.gov ↗
[3]
Drug with Neuroprotective Properties Noopept Does Not Stimulate Cell Proliferation (PMID 30788746)
pubmed.ncbi.nlm.nih.gov ↗
[4]
Effects of noopept on cognitive functions and pubertal process in rats with diabetes (PMID 31356906)
pubmed.ncbi.nlm.nih.gov ↗
[5]
The original novel nootropic and neuroprotective agent noopept (PMID 12596521)
pubmed.ncbi.nlm.nih.gov ↗
[6]
Neuroprotective Dipeptide Noopept Prevents DNA Damage in Mice with Modeled Prediabetes (PMID 31776952)
pubmed.ncbi.nlm.nih.gov ↗
[7]
Noopept normalizes parameters of the incretin system in rats with experimental diabetes (PMID 25065315)
pubmed.ncbi.nlm.nih.gov ↗
[8]
PsychonautWiki - Omberacetam
psychonautwiki.org ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT